# Benchmarking Lysosome Enrichment Methods: A Guide for Research and Clinical Translation

**Authors:** Anniek L. de Jager, Sara Kassem, Louis Alesha, Brigitta A.E. Naber, Inge F. de Laat, Bas de Mooij, Kyra van der Pan, Erik Bos, Roman I. Koning, Jacques J.M. van Dongen, Cristina Teodosio, Paula Díez

PMC · DOI: 10.1021/acs.analchem.5c05792 · Analytical Chemistry · 2026-02-03

## TL;DR

This paper compares different methods for isolating lysosomes to help researchers choose the best one for their needs.

## Contribution

The study provides a systematic, multimodal benchmark of lysosome enrichment techniques using a monocytic cell line.

## Key findings

- Gradient-based and bead-based methods offer the highest lysosomal enrichment and proteomic purity.
- Subcellular fractionation yields more lysosomes but with higher variability and contamination.
- Filter-based methods are fast but result in nonintact lysosomes with significant cross-contamination.

## Abstract

Lysosomes, essential organelles involved in diverse cellular
processes,
are increasingly recognized as central players in the pathogenesis
of numerous diseases. Due to their low abundance in whole-cell extracts,
enrichment strategies are required for downstream analyses such as
proteomics. Despite the availability of various lysosome isolation
methods, including density gradient-based separation, filter-based
approaches, magnetic bead-based isolation, and subcellular fractionation,
a systematic, multimodal comparison of their performance is lacking.
Here, four widely used lysosome enrichment techniques are benchmarked
using the THP-1 monocytic cell line as a model. Each method has been
evaluated for yield, purity, membrane integrity, reproducibility,
scalability, and cross-contamination, employing nanoparticle tracking
analysis, electron microscopy, flow cytometry, Western blotting, and
mass spectrometry-based proteomics. Data reveal substantial differences:
gradient-based and bead-based methods provide the highest lysosomal
enrichment and proteomic purity, whereas the subcellular fractionation
approach yields greater numbers of lysosomes but with increased variability
and contamination. Finally, the filter-based method enables rapid
processing, but mainly nonintact lysosomes are obtained with significant
cross-contamination. These findings provide practical guidance for
selecting the appropriate lysosome enrichment strategy, tailored to
specific research or clinical objectives. The results also emphasize
the need for rigorous validation to ensure the robustness of lysosomal
studies in both basic and clinical research settings.

## Full-text entities

- **Genes:** EEA1 (early endosome antigen 1) [NCBI Gene 8411] {aka MST105, MSTP105, ZFYVE2}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864] {aka NPC, POGZ, SLC65A1}, GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629] {aka GBA, GCB, GLUC}, TMEM192 (transmembrane protein 192) [NCBI Gene 201931], ABCD3 (ATP binding cassette subfamily D member 3) [NCBI Gene 5825] {aka ABC43, CBAS5, OPDM5, PMP70, PXMP1, ZWS2}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920] {aka CD107b, DND, LAMP-2, LAMPB, LGP-96, LGP110}, OGA (O-GlcNAcase) [NCBI Gene 10724] {aka MEA5, MGEA5, NCOAT}, COX4I1 (cytochrome c oxidase subunit 4I1) [NCBI Gene 1327] {aka COX IV-1, COX4, COX4-1, COXIV, COXIV-1, MC4DN16}, GOLGA2 (golgin A2) [NCBI Gene 2801] {aka DEDHMB, GM130}, CTSB (cathepsin B) [NCBI Gene 1508] {aka APPS, CPSB, KWE, RECEUP}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** Niemann-Pick disease type C (MESH:D052556), Parkinson's (MESH:D010300), acute monocytic leukemia (MESH:D007948), conditions (MESH:D020763), inflammatory (MESH:D007249), neurodegenerative diseases (MESH:D019636), LSDs (MESH:D016464), cancer (MESH:D009369), Alzheimer's (MESH:D000544), inflammatory bowel disease (MESH:D015212), atherosclerosis (MESH:D050197), rheumatoid arthritis (MESH:D001172), cardiovascular disorders (MESH:D002318)
- **Chemicals:** 2-iodoacetamide (MESH:D007460), iron (MESH:D007501), peptides (MESH:D010455), luminal (MESH:D010634), methylcellulose (MESH:D008747), H2O (MESH:D014867), GlutaMAX (MESH:C054122), ethanol (MESH:D000431), HCl (MESH:D006851), copper (MESH:D003300), SDS (MESH:D012967), DTT (MESH:D004229), Tricine (MESH:C100184), iron oxide (MESH:C000499), formic acid (MESH:C030544), MgCl2 (MESH:D015636), Calcein AM (MESH:C085925), Met (MESH:D008715), carbon (MESH:D002244), streptomycin (MESH:D013307), Triton X-100 (MESH:D017830), ACN (MESH:C032159), bromophenol blue (MESH:D001978), N (MESH:D009584), EDTA (MESH:D004492), digitonin (MESH:D004072), Calcein (MESH:C007740), lipid (MESH:D008055), sucrose (MESH:D013395), sodium pyrophosphate (MESH:C003319), CO2 (MESH:D002245), Tris-glycine (MESH:C035647), DMSO (MESH:D004121), PVDF (MESH:C024865), PBS (MESH:D007854), Lys (MESH:D008239), KCl (MESH:D011189), HEPES (MESH:D006531), glycerol (MESH:D005990), penicillin (MESH:D010406), Percoll (MESH:C016039), Dextran (MESH:D003911), LTDR (-), ammonium bicarbonate (MESH:C027043), uranyl acetate (MESH:C005460), urea (MESH:D014508), beta-glycerophosphate (MESH:C031463), PMSF (MESH:D010664), hydroxylamine (MESH:D019811)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.M393T, AGC at 200
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), ACC 16 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_6872), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921670/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921670/full.md

## References

84 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921670/full.md

---
Source: https://tomesphere.com/paper/PMC12921670